As municipal councils prepare to wrap up sessions with outgoing representatives and welcome newly-elected members, there are few meeting dates left for cities or townships to hold discussions ahead of the deadline set by the province to decide whether there should be a government marijuana store in their community.

The provincial government has set a deadline of Jan. 22, 2019 for municipalities to opt out of having a local cannabis retail store.

Thus far, only Guelph and North Dumfries have set dates for the issue to come before council. North Dumfries council will debate the issue on Dec. 10 while Guelph has it scheduled it for Dec. 17.

There is no doubt that marijuana stocks are from a highly speculative segment of the market, where it’s tough to come up with a credible valuation model based on the companies’ fundamentals.

Built into the prices of top marijuana stocks is hope and speculation that someday these companies will be highly profitable as more and more countries legalize the recreational use of pot, following the Canadian example.

But that doesn’t mean that there isn’t a long-term investment case for some top marijuana stocks. With this theme in mind, I have shortlisted two cannabis producers that fit the bill.

Canada’s more than 300,000 medical cannabis patients could soon have a new ally when filling their prescriptions.

In September, Health Canada approved Shoppers Drug Mart’s application to become a licensed producer (LP) of medical cannabis under the Access to Cannabis for Medical Purposes Regulations (ACMPR).

The approval paves the way for Canada’s largest drugstore chain to fill medical cannabis prescriptions through the mail. Currently under the ACMPR, all patients receive their prescription in the mail, direct from an LP.

“Medical Cannabis Is Just Like Every Other Prescription And Requires The Same Level Of Counsel From A Healthcare Professional”

– Theresa Firestone

FSD Pharma Inc.(CSE:HUGE), via its wholly-owned subsidiary FV Pharma, is a licensed producer of cannabis after receipt of its cultivation license under the Access to Cannabis for Medical Purposes Regulations (ACMPR) on October 13, 2017. The Company places emphasis on the development of the highest-quality indoor grown, pharmaceutical-grade cannabis as well as the research and development of cannabinoid-based treatments for several central nervous system disorders, including chronic pain, fibromyalgia and irritable bowel syndrome (IBS).

Canadians should expect pot prices to plummet in the coming years as more companies produce legal marijuana, with demand for cannabis flower expected to surpass 1 million pounds by 2022, according to one leading cannabis analyst.

Tom Adams, managing director of industry intelligence at BDS Analytics, a cannabis industry analysis firm, said Canadian marijuana prices should tumble in line with how the legal market performed alongside black market players in other markets such as Colorado. The price of pot has declined in that state by over 50 per cent in the past five years.

Province Brands ofCanada — the Canadian company developing the world's first beers brewed from the cannabis plant, including nonalcoholic beers which intoxicate using THC and other phytocannabinoids (to be released only when and where the sale of marijuana beverages are permitted by law) and Cambridge Bay Imperial Pilsner , a first-of-its-kind, 7% ABV imperial pilsner brewed from hemp in place of barley (which does not contain marijuana) — announces a co-packing and

There’s a shakeout coming to the Canadian cannabis industry and mid-sized companies may find it hardest to survive, according to the new president of Aphria Inc.

“There will be a group of companies at the top, the big producers, and some smaller producers at the bottom, like craft beer,” Jakob Ripshtein said in an interview at Bloomberg’s Toronto office. “I suspect there will be some in the middle who will be very challenged to stay around.”

The roll-out of legal cannabis is a prime example of how Canada can get things right. Energy shows how the country sometimes gets it wrong.

That’s the view of GMP Capital Inc.’s Harris Fricker, who is seeing deal-making in marijuana and blockchain eclipsing the traditional industries of energy and mining that were once bread-and-butter businesses for the Toronto-based financial services firm.

Just days after a ribbon-cutting ceremony to celebrate its grand opening, a medical marijuana company in Fort Erie has been purchased by a major player in the burgeoning weed market.

WeedMD Inc (TSX-V:WMD, OTCQX:WDDMF) said Tuesday that it has secured a license from Health Canada to sell cannabis cultivated at its greenhouse in Strathroy, Ontario.

The license allows the Toronto-based company to ship cannabis from the greenhouse to a nearby indoor facility in Aylmer, Ontario, for packaging and distribution to its medical and adult-use customers. The license, granted under the Cannabis Act, was originally issued under the Access to Cannabis for Medical Purposes Regulations.

“We are thrilled to secure approval to begin selling the medical-grade cannabis that we’ve been cultivating at our production facility in Strathroy,” CEO Keith Merker said in a statement. “The company continues to meet its production milestones on schedule and on budget.”